
Yuhan Corp
KRX:000100

Yuhan Corp's latest stock split occurred on Dec 27, 2023
The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.
Before the split, Yuhan Corp traded at 66571.4297 per share. Afterward, the share price was about 67900.
The adjusted shares began trading on Dec 27, 2023. This was Yuhan Corp's 25th stock split, following the previous one in Dec 28, 2022.
Yuhan Corp
Glance View
In the bustling landscape of South Korea's pharmaceutical industry, Yuhan Corp. stands out as a venerable institution with a rich legacy and a forward-thinking approach. Founded in 1926, Yuhan has carved out a respected space in the market through its commitment to developing, manufacturing, and distributing a wide array of pharmaceutical and healthcare products. The company operates across multiple segments, focusing on prescription drugs, over-the-counter medications, and consumer health products that cater to various needs from chronic diseases to everyday health care. Yuhan’s product portfolio includes a combination of in-house innovations and collaborations with global leaders, which has allowed it to build a sustainable revenue stream and secure a substantial market share both domestically and internationally. At the core of Yuhan's business model is the strategic integration of research and development with commercial prowess. The company invests significantly in R&D to stay ahead of industry trends and meet evolving patient needs. This focus on innovation is complemented by strategic partnerships and licensing agreements with international pharmaceutical corporations, allowing Yuhan to introduce groundbreaking therapies to the Korean market. Additionally, Yuhan capitalizes on its robust distribution network, ensuring wide accessibility and penetration of its products. These efforts not only reinforce Yuhan’s position as a leader in the pharmaceutical sector but also fuel its steady financial growth, providing a reliable return on investment through a combination of direct sales and strategic partnerships.
